中文
Home
Scientific Research
Research Field
Paper Publications
Patents
Published Books
Research Projects
Teaching Research
Teaching Resources
Teaching Information
Teaching Achievement
Awards and Honours
Enrollment Information
Student Information
My Album
Blog
Paper Publications
[1] 毛飞.Resveratrol alleviates inflammatory bowel disease by inhibiting JAK2/ STAT3 pathway activity via the reduction of O-GlcNAcylation of STAT3 in intestinal epithelial cells
[2] 毛飞.The emerging role of the gut microbiota and its application in inflammatory bowel disease
[3] 毛飞.CircHN1 affects cell proliferation and migration in gastric cancer
[4] 毛飞.CircRNAs as promising biomarkers of inflammatory bowel disease and its associated-colorectal cancer
[5] 毛飞.Cellular and molecular mediators of lymphangiogenesis in inflammatory bowel disease
[6] 毛飞.The Effects of Mesenchymal Stem Cell on Colorectal Cancer
[7] 毛飞.Resveratrol Attenuates Inflammatory Bowel Disease in Mice by Regulating SUMO1
[8] 王娟娟.HucMSC exosome-transported 14-3-3 zeta prevents the injury of cisplatin to HK-2 cells by inducing autophagy in vitro
[9] 毛飞.Mesenchymal stem cells and their therapeutic applications in inflammatory bowel disease
[10] 毛飞.Human umbilical cord mesenchymal stem cells alleviate inflammatory bowel disease through the regulation of 15-LOX-1in macrophages
[11] 毛飞.Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells Relieve Inflammatory Bowel Disease in Mice
[12] 赵婷,Nitin Tandra,毛飞.15-Lipoxygenase-1 suppression of colitis-associated colon cancer through inhibition of the IL-6/STAT3 signaling pathway
[13] Nitin Tandra,赵婷,毛飞.Emerging Role of Mesenchymal Stem Cell-derived Exosomes in Regenerative Medicine
[14] Nitin Tandra,赵婷,毛飞.Extracellular vesicles: a new nano tool for the treatment of inflammatory bowel diseases
[15] Xu, Xueying,王娟娟.LINC00978 promotes the progression of hepatocellular carcinoma by regulating EZH2-mediated silencing of p21 and E-cadherin expression
total15 1/1
first
previous
next
last
gajgljgfg
Click:
MOBILE Version
The Last Update Time:
.
.